Article Text

Download PDFPDF
Original article
β2-Adrenergic genotypes and risk of severe exacerbations in COPD: a prospective cohort study
  1. Truls Sylvan Ingebrigtsen1,2,3,
  2. Jørgen Vestbo4,5,
  3. Line Rode2,6,
  4. Jacob Louis Marott2,3,
  5. Peter Lange1,2,3,7,
  6. Børge G Nordestgaard2,3,6
  1. 1 Department of Respiratory Medicine, Hvidovre Hospital, Hvidovre and Amager Hospital, Copenhagen University Hospital, University of Copenhagen, Copenhagen, Denmark
  2. 2 The Copenhagen General Population Study, Herlev and Gentofte Hospital, Copenhagen University Hospital, University of Copenhagen, Copenhagen, Denmark
  3. 3 The Copenhagen City Heart Study, Frederiksberg Hospital, Bispebjerg and Frederiksberg Hospital, Copenhagen University Hospital, Copenhagen, Denmark
  4. 4 Division of Infection, Immunity and Respiratory Medicine, School of Biological Sciences, University of Manchester, Manchester, UK
  5. 5 Manchester Academic Health Science Centre, Manchester University NHS Foundation Trust, Manchester, United Kingdom
  6. 6 Department of Clinical Biochemistry, Herlev and Gentofte Hospital, Copenhagen University Hospital, University of Copenhagen, Copenhagen, Denmark
  7. 7 Section of Social Medicine, Institute of Public Health, University of Copenhagen, Copenhagen, Denmark
  1. Correspondence to Børge G Nordestgaard, Department of Clinical Biochemistry, Copenhagen University Hospital, Herlev DK-2730, Denmark; Boerge.Nordestgaard{at}regionh.dk

Abstract

Background Individual susceptibility to exacerbations in chronic obstructive pulmonary disease (COPD) is likely influenced by genetic factors; however, most such variance is unexplained. We hypothesised that β2-adrenergic receptor genotypes, Gly16Arg (rs1042713, c.46G>A) and Gln27Glu (rs1042714, c.79C>G) influence risk of severe exacerbations in COPD.

Methods Among 96 762 individuals in the Copenhagen General Population Study, we identified 5262 with COPD (forced expiratory volume in one second divided by forced vital capacity, FEV1/FVC, below 0.7, FEV1 less than 80% of predicted value, age above 40 years and no asthma) who had genotyping performed. Severe exacerbations were defined as acute admissions due to COPD during 5 years of follow-up (mean 3.4 years). 923 individuals with COPD diagnosed similarly in the Copenhagen City Heart Study (CCHS) were used for replication analyses.

Results We recorded 461 severe exacerbations in 5262 subjects. The HRs for severe exacerbations were 1.62 (95% CI 1.30 to 2.03, p=0.00002) for 16Gly/Arg heterozygotes and 1.41 (1.04 to 1.91, p=0.03) for 16Arg homozygotes, compared with 16Gly homozygotes. HRs were 1.35 (1.03 to 1.76, p=0.03) for 27Gln/Glu heterozygotes and 1.49 (1.12 to 1.98, p=0.006) for 27Gln homozygotes, compared with 27Glu homozygotes. Similar trends were observed in the CCHS. Among 27Gln homozygotes only, HRs were 5.20 (1.81 to 14.9, p=0.002) for 16Gly/Arg heterozygotes and 4.03 (1.40 to 11.6, p=0.01) for 16Arg homozygotes, compared with 16Gly homozygotes.

Conclusion Common β2-adrenergic receptor genotypes influence risk of severe exacerbations in COPD, potentially mainly by genetic influence of the 16Arg allele in rs1042713.

  • adrenoreceptor polymorphisms
  • COPD
  • precision medicine
View Full Text

Statistics from Altmetric.com

Footnotes

  • Contributors Study concept and design: TSI, JV, BGN, LR; acquisition of data: PL., BGN; analysis and interpretation of data: TSI, JLM, JV, BGN; critical revision of the manuscript: all authors; statistical analysis: TSI, JLM; obtained funding: PL, JV, BGN; study supervision: TSI, JV, BGN. All authors had full access to all the data in the study. TSI, BGN, and JLM take responsibility for the integrity of the data and the accuracy of the data analysis, and for the submission.

  • Funding Supported by the Capital Region of Copenhagen, the Danish Heart Foundation, the Danish Lung Foundation, the Velux Foundation, and Herlev and Gentofte Hospital. JV is supported by the NIHR Manchester Biomedical Research Centre.

  • Competing interests TSI has received a fee for speaking from AstraZeneca. JV has received honoraria from Chiesi, GlaxoSmithKline, Almirall, AstraZeneca, Boehringer-Ingelheim, and Novartis for consulting and for presenting at meetings and symposia, none of it related to the topic of this study. LR and JLM: none to declare. PL has received honoraria from AstraZeneca, Boehringer Ingelheim, Chiesi, Novartis, Teva, and GlaxoSmithKline for presenting at meetings and symposia, none of it related to the topic of this study. BGN: none to declare.

  • Patient consent for publication Not required.

  • Provenance and peer review Not commissioned; externally peer reviewed.

  • Data availability statement No data are available.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Linked Articles